IL22 and myeloid sarcoma: In MS patients, IL-22 is upregulated in their serum and peripheral blood mononuclear cells (PBMCs) compared with serum and PBMCs of healthy controls, and IL-22 levels are higher in patients with active disease than in those with inactive disease (60).